Aarti Drugs Limited has announced the incorporation of a new step-down subsidiary in Chile, expanding its international pharmaceutical operations through its existing subsidiary structure. The company disclosed this development under Regulation 30 of the SEBI Listing Regulations on March 2, 2026.

New Subsidiary Formation

The newly incorporated entity, Tripharma Chile SpA, was established on February 27, 2026, through Pinnacle Chile SpA, which is already a subsidiary of Aarti Drugs Limited. The certificate of registration was processed by the Registry of Companies and Societies, Government of Chile, on February 27, 2026, with company officials being notified on March 2, 2026.

Business Operations and Objectives

Tripharma Chile SpA will operate in the pharmaceutical industry, focusing on marketing formulation drugs and participating in both tender and private markets in Chile. The company's business model aligns with the operations of its holding companies, maintaining consistency within the Aarti Drugs group's pharmaceutical focus.

Corporate Structure

The incorporation creates a multi-tiered subsidiary structure where Tripharma Chile SpA becomes a step-down subsidiary of Aarti Drugs Limited. Pinnacle Chile SpA, which is a direct subsidiary of Aarti Drugs Limited, holds 100% shareholding in the newly formed Tripharma Chile SpA. This structure allows Aarti Drugs to maintain operational control while establishing a local presence in the Chilean pharmaceutical market.

Financial and Regulatory Details

The incorporation involved a cash consideration of Chilean Peso 10,00,000 as share capital contribution, distributed across 10,00,000 shares. The company confirmed that no specific governmental or regulatory approvals were required for this incorporation, streamlining the establishment process in Chile.

This strategic move represents Aarti Drugs Limited's continued expansion in international markets, particularly in South America, through its pharmaceutical operations and subsidiary network.

Aarti Drugs announced its audited financial results for Q3FY26, demonstrating robust growth in profitability alongside strategic capacity expansion initiatives. The pharmaceutical company's Board of Directors also declared an interim dividend of ₹2 per equity share for FY26.

Q3FY26 Financial Performance

The company delivered strong consolidated financial results for the quarter with significant improvement in profitability metrics. Revenue growth was driven by healthy domestic market traction and exceptional performance in the export formulations segment.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, the company demonstrated consistent growth momentum with strong performance across both revenue and profitability parameters.

Segmental Performance Highlights

The company's diversified business portfolio showed mixed performance across segments, with formulations and specialty chemicals leading growth momentum.

Board Decisions and Corporate Actions

The Board of Directors approved several key decisions during their meeting held on February 3, 2026. The company declared an interim dividend of ₹2 per equity share (20%) for FY26, with February 9, 2026 fixed as the record date for dividend payment.

Manufacturing Expansion and Operational Updates

According to CFO & COO Adhish Patil, the company successfully operationalized key growth projects during the quarter. The backward integration plant in Sayakha for methyl amines achieved 30% capacity utilization in its first quarter of operations, with plans to reach 50% by March or April 2026. The facility currently fulfills 10-15% of captive Metformin requirements, with expectations to achieve 100% self-reliance within 6-8 months.

The Salicylic Acid plant in Tarapur reached a significant milestone, scaling to above 300 tonnes per month. The downstream Salicylates line implementation is expected to transform this segment into a primary value driver for the company.

Senior Management Appointments

The Board approved the inclusion of three functional heads in the list of Senior Management Personnel, effective February 3, 2026: